Alexios Matikas: We show for the first time the superiority of dose dense versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer

Alexios Matikas, Associate Professor of Oncology at Karolinska Institute, shared on LinkedIn:

“Dose dense is the optimal schedule of adjuvant chemotherapy for high risk breast cancer. However, prior trials have mostly compared dose dense regimens to control arms containing the inferior paclitaxel every three weeks regimen. With the phase 3 PANTHER trial (n=2017), just published at the Journal of Clinical Oncology (IF=42.1), we show for the first time the superiority of dose dense chemotherapy over an optimal control of sequential anthracycline and docetaxel.

Big thanks to the Swedish, German and Austrian Breast Cancer Groups, Karolinska University Hospital and Karolinska Institute, all investigators – especially the corresponding author Theodoros Foukakis and the trial’s PI Jonas Bergh, and of course all study participants and their families.

‘Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial‘

Authors: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis, and Jonas Bergh.

Source: Alexios Matikas/LinkedIn